Active Ingredient History
Trametinib is a reversible and specific inhibitor of mitogen-activated protein kinase kinases MEK1 and MEK2 which are involved in a RAS/RAF/MEK/ERK signaling pathway and control cell growth, survival, and differentiation. By inhibiting MEK1 and MEK2 trametinib blocks dual phosphorylation of ERK1/2 and stops cell cycling. In addition, trametinib blocks BRAF pathway in the cells with BRAF V600E mutations. Trametinib (as a single agent and in combination with dabrafenib) is approved for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 2)
Adenocarcinoma of Lung (Phase 1/Phase 2)
Adenoma, Oxyphilic (Phase 2)
Amyotrophic Lateral Sclerosis (Phase 1/Phase 2)
Anemia (Phase 1)
Astrocytoma (Phase 4)
Bile Duct Neoplasms (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Bronchial Neoplasms (Phase 1)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Central Nervous System Neoplasms (Phase 1)
Child (Phase 2)
Cholangiocarcinoma (Phase 2)
Choroid Plexus Neoplasms (Phase 1)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Dermatology (Phase 2)
Endometrial Neoplasms (Phase 2)
Ependymoma (Phase 1)
Epidermal Growth Factor (Phase 2)
ErbB Receptors (Phase 1)
Erdheim-Chester Disease (Phase 2)
Esophageal Neoplasms (Phase 2)
Gallbladder Neoplasms (Phase 2)
Ganglioglioma (Phase 4)
Ganglioneuroma (Phase 4)
Gastrointestinal Stromal Tumors (Phase 2)
Glioblastoma (Phase 4)
Glioma (Phase 4)
Hamartoma (Phase 2/Phase 3)
Hemangioendothelioma (Phase 2)
Histiocytosis (Phase 2)
Hodgkin Disease (Phase 1)
Kidney Neoplasms (Phase 2)
Klatskin Tumor (Phase 2)
Leukemia (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Leukemia, Myelomonocytic, Juvenile (Phase 2)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, Non-Hodgkin (Phase 1)
Medulloblastoma (Phase 1)
Melanoma (Phase 4)
Meningioma (Phase 1)
Metaplasia (Phase 1)
Mouth Neoplasms (Phase 2)
Multiple Myeloma (Phase 2)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 1)
Neoplasm Metastasis (Phase 2)
Neoplasms ()
Neoplasms, Germ Cell and Embryonal (Phase 1)
Neoplasms, Neuroepithelial (Phase 1)
Neuroblastoma (Phase 1)
Neurocytoma (Phase 4)
Neuroectodermal Tumors, Primitive (Phase 1)
Neurofibroma, Plexiform (Phase 2)
Neurofibromatosis 1 (Phase 4)
Oligodendroglioma (Phase 4)
Ovarian Neoplasms (Phase 2/Phase 3)
Pancreatic Neoplasms (Phase 2)
Paraganglioma (Phase 4)
Peripheral Arterial Disease (Phase 2)
Pinealoma (Phase 1)
Primary Myelofibrosis (Phase 1)
Prostatic Neoplasms (Phase 2)
Proto-Oncogene Proteins B-raf (Phase 2)
ras Proteins (Phase 2)
Rhabdoid Tumor (Phase 1)
Sarcoma (Phase 3)
Skin Neoplasms (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
Thyroid Cancer, Papillary (Phase 2)
Thyroid Carcinoma, Anaplastic (Phase 2)
Thyroid Neoplasms (Phase 3)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Venous Cutdown (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
